Skip to main content
I

InterVenn

InterVenn Biosciences utilizes its GlycoVision™ platform to conduct high-resolution glycoproteomic analysis, enabling the discovery of biomarkers for disease detection and therapeutic response. By examining protein glycosylation, the company provides critical insights into the molecular mechanisms of health and disease, facilitating personalized and preventive healthcare solutions.

South San Francisco, United StatesFounded 2017637K+ followers
Updated 20 months ago

Funding

$244.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

SC
Funding rounds are not available yet.

Founders

Product

Problem

Current methods for biomarker discovery, disease detection, and therapeutic monitoring often overlook the information encoded in protein glycosylation, a critical post-translational modification. This omission limits the ability to fully understand the molecular mechanisms of health and disease, hindering the development of personalized and preventive healthcare solutions.

Solution

InterVenn Biosciences offers the GlycoVision™ platform, a high-resolution glycoproteomic analysis solution that enables the discovery of novel biomarkers. By examining protein glycosylation patterns, GlycoVision™ provides insights into disease detection, progression, and therapeutic response. The platform's ability to analyze the glycoproteome at scale unlocks a previously untapped layer of biology, offering a more complete understanding of molecular mechanisms. This comprehensive approach facilitates the development of personalized medicine strategies and improves patient outcomes.

Target Audience

The primary audience includes researchers, clinicians, and pharmaceutical companies involved in biomarker discovery, drug development, and personalized medicine.

Features

  • High-resolution glycoproteomic analysis for detailed characterization of protein glycosylation
  • Biomarker discovery for disease detection, progression monitoring, and therapeutic response prediction
  • Proprietary platform designed to improve the speed, scope, and scale of glycoproteomic analysis
  • Identification of glycosylation patterns that control immune cell activation and distinguish specific physiological states
  • Clinically meaningful insights into the molecular mechanisms underlying health and disease
This profile is AI-generated and may contain inaccuracies.